Cantex & Headlamp Health Partner On AI For Precision Neuropsychiatry To Support Clinical Drug Development

Cantex Pharmaceuticals, Inc. (Cantex) and Headlamp Health (Headlamp) announced a collaboration to apply Headlamp's Lumos artificial intelligence (AI) platform to support the clinical development of azeliragon, a medication for severe depression and fatigue in people with multiple sclerosis (MS).

Lumos AI is a neuro-symbolic, multi-agent platform built for neuropsychiatric drug development. It integrates biological, behavioral, biomarker, and clinical data to help development teams identify responder and non-responder subtypes earlier, refine trial design, and model consumer trajectories that episodic data alone cannot capture. The platform draws on more than 100 million longitudinal, multi-modal data points and . . .